FDA granted approvals for Bristol Myers Squibb's Cobenfy (formerly KarXT) for schizophrenia, Johnson and Johnson's Tremfya for ulcerative colitis and Servier's Voranigo for IDH-mutant glioma, a type ...

After his arrest, he told a forensic psychiatrist that this drove his offending, saying he goes “crazy” without tobacco. A ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Discover how metabolic ketogenic therapy differs from the popular diet trend and its potential benefits for bipolar disorder.

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

Canadian officials show that reviewing emerging supply chain issues and taking steps to limit potential problems worked in its favor. Also in the news: noncompete bans, schizophrenia drugs, baby ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

Supporters say psychedelics alleviate treatment-resistant conditions like PTSD and depression. Opponents cite health risks ...

The company has laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...